Ongoing Project: To demonstrate that strengthening the immune system can improve the quality of life of Children with SCD
PROJECT ACEMANNAN & SICKLE CELL DISEASE: OUR GOAL
We are examining the role of the aloe vera leaf extract, Acemannan in improving the quality of life and reducing the frequency of painful crises and complications of sickle cell disease patients. In addition, we also aim to establish it as an adjunct in the management of sickle cell disease.
We hoped to collaborate with a centre, Sickle Cell Foundation Nigeria (SCFN).
The goal of this project in SCFN is to recruit 100 patients, from 1 year to 12 years, with sickle cell disease and split them into two groups. While one group receives both the routine drugs (folic acid and palludrine), the other group receives both routine drugs and acemannan.
Dr. Annette Akinsete
Confirming the Approval of the SCFN Board for us to conduct the research.
Research Meeting
Our research staff during the first meeting with the SCFN team, headed by the CEO of SCFN, Dr. Annette Akinsete.
Research Meeting
Photos from the Research Meeting.
Research Approval Letter
An approval letter from the SCFN for the research
The research activities started on the 25th day of April 2022. So far, we have recruited 105 participants for the study (52 participants in the routine group and 53 participants in the Acemannan group).
The total budget for the research is $14,271 (that $2,378 to be paid monthly), but this does not include the volunteer stipends and stipends/travel expenses for the Brain and Body Foundation research personnel.
Media Splash
Pictures from the first day and a batch of patients and parents starting the research project.
Solomon Adomi our head of research, along with the executives and officials of SCFN at the ongoing research project in Lagos, Nigeria.
Volunteer Report
Our research volunteer describing the research process.BBF Partnerships
Videos from the recently concluded annual Alovea convention.
MannaRelief executives and founders talking about the work we are doing, etc.